{"id":483,"date":"2009-11-01T12:03:00","date_gmt":"2009-11-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/haeufigkeit-von-thromboembolien-unter-oralen-kontrazeptiva-mit-unterschiedlichen-gestagenen"},"modified":"2009-11-01T12:03:00","modified_gmt":"2009-11-01T11:03:00","slug":"haeufigkeit-von-thromboembolien-unter-oralen-kontrazeptiva-mit-unterschiedlichen-gestagenen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2009\/haeufigkeit-von-thromboembolien-unter-oralen-kontrazeptiva-mit-unterschiedlichen-gestagenen","title":{"rendered":"H\u00e4ufigkeit von Thromboembolien unter oralen Kontrazeptiva mit unterschiedlichen Gestagenen"},"content":{"rendered":"<p>Wir haben 1996 und 1997 ausf\u00fchrlich \u00fcber Studien berichtet, die daf\u00fcr zu sprechen schienen, dass orale Kontrazeptiva (OK) mit relativ niedrigem Gehalt an Ethinylestradiol (EE) und den damals neuen Gestagenen der sog. 3. Generation (Gestoden, Desogestrel) h\u00e4ufiger ven\u00f6se Thrombosen\/Thromboembolien (VTE) verursachen als solche der 2. Generation (Levonorgestrel = LNG, Norethisteron; 1, 2). Alle genannten Gestagene [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben 1996 und 1997 ausf\u00fchrlich \u00fcber Studien berichtet, die daf\u00fcr zu sprechen schienen, dass orale Kontrazeptiva (OK) mit relativ niedrigem Gehalt an Ethinylestradiol (EE) und den damals neuen Gestagenen der sog. 3. Generation (Gestoden, Desogestrel) h\u00e4ufiger ven\u00f6se Thrombosen\/Thromboembolien (VTE) verursachen als solche der 2. Generation (Levonorgestrel = LNG, Norethisteron; 1, 2). Alle genannten Gestagene [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[58,61,273,272,885,886,888,890,64,67,415,892,887,891,889,54,51,55,52],"class_list":["post-483","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikonzeptiva","tag-beinvenenthrombose","tag-cyproteronacetat","tag-cyproteronazetat","tag-drospirenon","tag-euras-studie","tag-gestagene","tag-gestoden","tag-kontrazeption","tag-kontrazeptiva","tag-levonorgestrel","tag-mega-studie","tag-norethisteron","tag-ovulationshemmer","tag-pille","tag-thromboembolie","tag-thrombose","tag-venenthrombose","tag-verhuetung"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=483"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/483\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}